Body composition's impact on MAFLD resolution: insights from bariatric surgery in an Eastern-Asian context

<u>Ting-Wei Chang ^{1,2*}</u>, Ivy Ya-Wei Huang ^{2,3}, Ming-Lung Yu^{4,5}, Chih-Kun Huang ⁶, Po-Chih Chang^{1,2,7}

1 Division of Thoracic Surgery, Department of Surgery, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan
2 Weight Management Center, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan
3 Department of Nursing, Kaohsiung Medical University Hospital/Kaohsiung Medical University, Kaohsiung City, Taiwan
4 Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital; College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
5 School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver. National Sun Yat-sen University, Kaohsiung, Taiwan.
6 Body Science and Metabolic Disorders International Medical Center, China Medical University Hospital, Taichung City, Taiwan
7 School of Medicine, College of Medicine, National Sun Yat-sen University

XXVII IFSO World Congress



CONFLICT OF INTEREST DISCLOSURE

In accordance with «EACCME criteria for the Accreditation of Live Educational Events», please disclose whether you have or not any conflict of interest with the companies:

If you don't have any conflict, please delete the conflict of interest report points:

[V] I have no potential conflict of interest to report

[] I have the following potential conflict(s) of interest to report:

- Type of affiliation / financial interest:
- Receipt of grants/research supports:
- Receipt of honoraria or consultation fees:
- Participation in a company sponsored speaker's bureau:
- Stock shareholder:
- Spouse/partner:
- Other support (please specify):

XXVII IFSO World Congress



- Visceral fat is directly associated with liver inflammation and fibrosis independent of insulin resistance and hepatic steatosis.
- Visceral fat should therefore be a central target for future interventions in nonalcoholic steatohepatitis and indeed all metabolic disease.
- This study aims to investigate the potential influencing factor of body composition and MAFLD resolution.





van der Poorten D, *Hepatology*. 2008;48(2):449-457.

Liver-kidney contrast

Bioelectrical Impedance Analysis

XXVII IFSO World Congress



- Our retrospective study analyzes patient data from an Asian center specializing in weight management, spanning <u>August 2016 to October 2023.</u>
- We examined <u>208 consecutive patients</u> who underwent bariatric procedures, including laparoscopic sleeve gastrectomy (LSG) and laparoscopic Roux-en-Y gastric bypass (LRYGB), at our advanced medical facility.
- The study focused on <u>63 individuals</u> with severe obesity who were evaluated using abdominal ultrasound and body composition analysis one year following surgery. <u>(40 LSG and 23 LRYGB)</u>



Table1 Demographic				
	Total (n=63)	LSG (n=40)	LRYGB (n=23)	<i>P</i> value
Age (years)	37.02 ± 10.60	35.3 ± 9.04	40 ± 12.54	0.124
Body height (cm)	168.29 ± 8.99	168.4 ± 9.75	168.1 ± 7.69	0.901
Body weight (kg)	120.24 ± 24.52	113.70 ± 20.01	131.63 ± 27.76	0.004
BMI (kg/m2)	42.37 ± 7.48	39.94 ± 4.96	46.60 ± 9.20	0.003
Preoperative body fat (%)	46.66 ± 7.15	45.95 ± 5.90	47.90 ± 8.93	0.354
Preoperative trunk fat (kg)	24.20 ± 4.30	23.62 ± 3.99	25.20 ± 4.72	0.16
Preoperative visceral fat area (VFA)(cm ²)		227.02 ± 30.96	228.1 ± 43.34	0.909
Preoperative skeletal muscle mass	35.64 ± 7.67	34.58 ± 7.89	37.48 ± 7.08	0.149
Body weight 12 months after surgery		84.11 ± 18.73	89.67 ± 15.08	0.238
Body fat 12 months after surgery(%)	$44 \times 17 \times 104$	34.07 ± 7.80	33.36 ± 11.01	0.792
Trunk fat 12 months after surgery (kg)	$ 6.0 \pm 3.59 $	16.97 ± 16.55	14.35 ± 5.68	0.476
VFA12 months after surgery (cm2)	136.2 ± 47.94	133.98 ± 45.15	140.04 ± 53.31	0.641
Skeletal muscle mass 12 months after surgery	3130 ± 750	30.81 ± 8.36	32.14 ± 5.87	0.514

	Fatty liver improved		Fatty liver resolution	
	F	P value	F	<i>P</i> value
Gender	1.766	0.164	1.134	0.291
Age	1.249	0.3	2.035	0.159
Body Weight	3.302	0.026	6.998	0.01
Preoperative diabetes mellitus	0.783	0.508	0.138	0.711
Preoperative body fat (%)	1.455	0.236	4.494	0.038
Preoperative trunk fat (kg)	3.799	0.015	10.669	0.002
Preoperative Visceral Fat Area (VFA) (cm2)	6.48	<.001	16.085	<.001
Preoperative skeletal muscle mass (kg)	1.051	0.377	1.034	0.313



	Univariate Regression Analysis		Multivariate Regression Analysis	
	95% CI	P value	95% CI	P value
Body Weight (kg)	0.002±0.012	0.011	-0.005±0.01	0.447
Preoperative Body fat(%)	0.001±0.036	0.038	-0.04±0.013	0.303
Preoperative trunk fat (kg)	0.017±0.073	0.002	-0.067±0.049	0.759
Preoperative Visceral Fat Area (VFA) (cm ²)	0.003±0.01	<.001	0.002±0.015	0.016



- Our findings emphasize the critical role of visceral fat reduction in the remission of MAFLD following bariatric surgery in Eastern-Asian populations.
- The study confirms bariatric surgery's effectiveness in treating obesity-induced liver conditions and highlights the significance of targeting visceral adiposity.
- These results advocate for more research to develop tailored treatment strategies that improve MAFLD outcomes, thus enhancing the surgical management of liver diseases.



